Page last updated: 2024-09-05

deferasirox and Thalassemias

deferasirox has been researched along with Thalassemias in 94 studies

Research

Studies (94)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (15.96)	29.6817
2010's	62 (65.96)	24.3611
2020's	17 (18.09)	2.80

Authors

Authors	Studies
Akinel, A; Guler, E; Kintrup, GT; Kupesiz, A; Kupesiz, FT; Sivrice, C	1
Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J	1
Aydinok, Y; Cappellini, MD; Govindaraju, S; Izquierdo, M; Karakas, Z; Kattamis, A; Lai, YR; Lasher, J; Liu, R; Porter, J; Siritanaratkul, N; Taher, A; Viprakasit, V	1
Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ	1
Badawy, SM; Shah, A; Shah, R	1
Al-Bagshi, M; Chuncharunee, S; Dung, PC; Hamdy, MM; Hassab, HMA; Khattab, M; Küpesiz, A; Perez, LT; Shekhawat, A; Sherief, LM; Slader, C; Sonawane, Y; Taher, AT; Viprakasit, V	1
Daprile, C; Dello Iacono, N; Frappampina, R; Mosna, F; Palma, A; Pasanisi, A; Pastore, D; Quarta, A; Renni, R; Serra, M; Sgherza, N; Solfrizzi, MP; Visceglie, D; Vitucci, A	1
Arighi, C; Cappellini, MD; Cassinerio, E; Consonni, D; Graziadei, G; Marcon, A; Motta, I; Scaramellini, N	1
Delhikumar, CG; DivakarJose, RR; Ram Kumar, G	1
Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V	1
Akramipour, R; Fattahi, N; Golpayegani, MR	1
Allò, M; Campisi, S; Casale, M; Cassinerio, E; Cattoni, A; De Michele, E; Di Concilio, R; Ferrara, F; Forni, GL; Ladogana, S; Lazzarino, AI; Marcon, A; Notarangelo, LD; Origa, R; Pasquali, D; Peluso, A; Perrotta, S; Picariello, S; Poggi, M; Putti, MC; Quarta, A; Renni, R; Roberti, D; Sau, A; Serra, M; Sportelli, F; Sturiale, P; Tartaglione, I	1
Bansal, D; Peyam, S	1
Akıcı, F; Arslantaş, E; Ayçiçek, A; Aydoğan, G; Bayram, C; Odaman Al, I; Özdemir, GN; Şalcıoğlu, Z; Uysalol, EP; Zengin Ersoy, G	1
Chhabra, IK; Ibrahim, HM; Mohammed, NS; Shafie, AA; Wong, JHY	1
Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ	1
Allegra, S; Berchialla, P; De Francia, S; Ferrero, GB; Longo, F; Piga, A; Piolatto, A	1
Ambrogio, AG; Baldini, M; Cassinerio, E; Mancarella, M; Marcon, A; Motta, I	1
Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK	1
Kolnagou, A; Kontoghiorghes, GJ	1
Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y	1
Sivaramakrishnan, G; Sridharan, K	1
Aydinok, Y; Kattamis, A; Taher, A	1
Sari, TT; Wahidiyat, PA; Yosia, M	1
Bacigalupo, L; Balocco, M; De Franceschi, L; Forni, GL; Gianesin, B; Malagò, R; Pinto, VM; Quintino, S; Rizzi, M	1
Fogel, MA; Hammond, J; Hammond, K; Kokroko, J; Kwiatkowski, JL; Thompson, AA	1
Akın, M; Akkaynak, D; Antmen, B; Apak, H; Aral, YZ; Aydogan, G; Ayhan, AC; Biner, B; Çalışkan, Ü; Eren, TG; Ertem, M; Gümrük, F; İrken, G; Işık Balcı, Y; Karakaş, Z; Karasu, G; Kazancı, EG; Koç, A; Koçak, Ü; Küpesiz, OA; Kurtoğlu, E; Meral Güneş, A; Oktay, G; Oymak, Y; Patıroğlu, T; Salcioglu, Z; Şaşmaz, İ; Söker, M; Timur, Ç; Tunç, B; Türkkan, E; Ünal, S; Uygun, V; Vergin, C; Yeşilipek, MA; Yıldırmak, Y	1
Chen, G; Dou, H; Qin, Y; Zhao, Y	1
Argenziano, M; Casale, M; Perrotta, S; Punzo, F; Rossi, F; Tortora, C	1
Belhoul, K; Bobbili, P; Bruederle, A; Duh, MS; Han, J; Huang, V; Kouraklis, A; Origa, R; Perrotta, S; Porter, JB; Taher, AT	1
Hagar, RW	1
Caruso, V; Cuccia, L; D'Ascola, DG; Di Maggio, R; Filosa, A; Giangreco, A; Maggio, A; Masera, N; Pepe, A; Pitrolo, L; Rigano, P; Ruffo, GB; Vitrano, A	1
Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y	1
Pongtanakul, B; Viprakasit, V	1
Kontoghiorghes, GJ	4
Brittenham, GM; Olivieri, NF	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z	1
Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ	1
Cappellini, MD; Taher, AT; Temraz, S	1
Habr, D; Huang, SL; Lai, YR; Li, CF; Li, Q; Liu, RR; Martin, N; Shen, ZX	1
Huang, L; Jiang, H; Xia, S; Zhang, W	1
Cappellini, MD; Chuncharunee, S; Habr, D; Karakas, Z; Kattamis, A; Origa, R; Porter, JB; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z	2
Plosker, GL; Shirley, M	1
Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V	1
Haghpanah, S; Karimi, M	1
Chuang, GT; Lu, MY; Tsai, IJ; Tsau, YK	1
Adil, SN; Shaikh, MS	1
Bottaro, G; Clementi, E; Deodato, F; Dionisi-Vici, C; Falvella, FS; Goffredo, B; Marano, M; Marinaro, AM; Pisani, M; Stoppa, F	1
Marsella, M; Ricchi, P	1
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S	1
Aydinok, Y; Cappellini, MD; Joaquin, V; Karakas, Z; Kattamis, A; Lai, YR; Porter, JB; Siritanaratkul, N; Taher, AT; Uwamahoro, MJ; Viprakasit, V; Wang, C; Zhu, Z	1
Kontoghiorghe, CN; Kontoghiorghes, GJ	1
Gomber, S; Jain, P; Narang, M; Sharma, S	1
Beydoun, HG; Saliba, AN; Taher, AT	1
Deghedy, MR; Ebeid, WM; El-Shazly, AA; Elkitkat, RS	1
Chuansumrit, A; Kadegasem, P; Khlairit, P; Mahachoklertwattana, P; Pengpis, P; Poomthavorn, P; Sirachainan, N; Sungkarat, W; Wongwerawattanakoon, P	1
Aydinok, Y; El-Ali, A; El-Beshlawy, A; Elalfy, M; Han, J; Lee, SH; Porter, JB; Sutcharitchan, P; Taher, A	1
Cortoos, A; Goh, AS; Huang, V; Kattamis, A; Kourakli, A; Merino Herranz, R; Origa, R; Perrotta, S; Porter, JB; Ruffo, GB; Taher, AT; Weill, M	1
Barada, K; Khalife, M; Musallam, KM; Taher, AT	1
Chan, GC; Chan, S; Ha, SY; Ho, PL	1
Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y	1
Cappellini, MD; Taher, A	1
Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V	1
Agarwal, MB	1
Jetsrisuparb, A; Jetsrisuparb, C; Komvilaisak, P; Wiangnon, S	1
Hershko, C	1
Porter, JB; Shah, FT	1
Berdoukas, V; Coates, T; Farmaki, K; Wood, JC	1
Bowden, DK; Chan, LL; Chiu, CF; Domokos, G; Ha, SY; Habr, D; Ho, PJ; Ibrahim, H; Li, CK; Lin, KH; Roubert, B; Sutcharitchan, P; Viprakasit, V; Xue, HL	1
Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R	1
Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R	1
Kohli, S; Saxena, R; Verma, IC	1
Pankaew, T; Torcharus, K	1
Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G	1
De Francia, S; Di Carlo, F; Massano, D; Piccione, FM; Piga, A; Pirro, E; Racca, S	1
Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ	1
Gaur, A	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, J; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y	1
Marks, PW	1
Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT	1
Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E	1
Nathan, DG	1
Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ	1
Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G	1
Fischer, R; Harmatz, P; Nielsen, P; Piga, A	1
Dubey, AP; Parakh, A; Sudha, S	1
Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E	1
Berdoukas, V; Modell, B	1
Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R	1

Reviews

25 review(s) available for deferasirox and Thalassemias

Article	Year
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in bioscience (Elite edition), 2022, 07-12, Volume: 14, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles	2022
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2017, 08-15, Volume: 8 Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles	2017
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6 Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles	2018
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. European journal of haematology, 2018, Volume: 101, Issue:3 Topics: Blood Transfusion; Chelation Therapy; Deferasirox; Disease Management; Humans; Iron Chelating Agents; Iron Overload; Liver Function Tests; Medication Adherence; Myelodysplastic Syndromes; Thalassemia; Treatment Outcome	2018
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta medica Indonesiana, 2018, Volume: 50, Issue:2 Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles	2018
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. Acta haematologica, 2019, Volume: 141, Issue:1 Topics: Databases, Factual; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Odds Ratio; Thalassemia	2019
Management of the thalassemias. Cold Spring Harbor perspectives in medicine, 2013, Jun-01, Volume: 3, Issue:6 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles	2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles	2013
Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert review of hematology, 2013, Volume: 6, Issue:5 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Triazoles	2013
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PloS one, 2013, Volume: 8, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles	2013
Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Drugs, 2014, Volume: 74, Issue:9 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles	2014
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2015, Volume: 9 Topics: Benzoates; Biomarkers; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Syndrome; Thalassemia; Treatment Outcome; Triazoles	2015
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles	2016
Deferasirox: oral, once daily iron chelator--an expert opinion. Indian journal of pediatrics, 2010, Volume: 77, Issue:2 Topics: Benzoates; Cardiovascular Diseases; Chelating Agents; Deferasirox; Expert Testimony; Hemosiderosis; Humans; Iron; Liver; Thalassemia; Triazoles	2010
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2010
Past, present & future scenario of thalassaemic care & control in India. The Indian journal of medical research, 2011, Volume: 134 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; India; Male; Preimplantation Diagnosis; Prenatal Diagnosis; Pyridones; Thalassemia; Triazoles	2011
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2 Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Thalassemia; Triazoles	2012
Iron mobilization using chelation and phlebotomy. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2012, Volume: 26, Issue:2-3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles	2012
Clinical research: a tale of two studies. Transactions of the American Clinical and Climatological Association, 2003, Volume: 114 Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug Industry; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Triazoles	2003
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles	2005
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles	2005
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles	2006
Deferasirox: the new oral iron chelator. Indian pediatrics, 2007, Volume: 44, Issue:8 Topics: Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Chelating Agents; Thalassemia; Triazoles	2007
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2008

Trials

20 trial(s) available for deferasirox and Thalassemias

Article	Year
Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study. Journal of pharmacy practice, 2023, Volume: 36, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Triazoles	2023
Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia. Annals of hematology, 2023, Volume: 102, Issue:8 Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Preference; Tablets; Thalassemia	2023
A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L. American journal of hematology, 2020, Volume: 95, Issue:9 Topics: Blood Transfusion; Chelation Therapy; Deferasirox; Female; Ferritins; Humans; Male; Thalassemia	2020
Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:1 Topics: Adult; Blood Transfusion; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Iron Overload; Male; Pilot Projects; Thalassemia	2019
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. American journal of hematology, 2019, Volume: 94, Issue:4 Topics: Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Medication Adherence; Myelodysplastic Syndromes; Patient Reported Outcome Measures; Tablets; Thalassemia	2019
Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial. British journal of haematology, 2019, Volume: 186, Issue:6 Topics: Adult; Blood Transfusion; Deferasirox; Deferiprone; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Thalassemia	2019
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. American journal of hematology, 2013, Volume: 88, Issue:6 Topics: Adult; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Thalassemia; Triazoles; Young Adult	2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of hematology, 2013, Volume: 92, Issue:11 Topics: Benzoates; Blood Transfusion; Cross-Over Studies; Deferasirox; Double-Blind Method; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Time Factors; Treatment Outcome; Triazoles	2013
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. Transfusion medicine (Oxford, England), 2013, Volume: 23, Issue:6 Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Benzoates; Child; Child, Preschool; China; Deferasirox; Female; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Thalassemia; Triazoles	2013
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. European journal of haematology, 2014, Volume: 92, Issue:6 Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles	2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. British journal of haematology, 2015, Volume: 168, Issue:2 Topics: Adolescent; Adult; Benzoates; Deferasirox; Double-Blind Method; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Thalassemia; Triazoles; Young Adult	2015
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood cells, molecules & diseases, 2016, Volume: 57 Topics: Adolescent; Adult; Benzoates; Blood Transfusion; Chelation Therapy; Child; Deferasirox; Diarrhea; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Nausea; Thalassemia; Treatment Outcome; Triazoles	2016
Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia. Acta haematologica, 2017, Volume: 137, Issue:1 Topics: Adolescent; Benzoates; Blood Glucose; Blood Transfusion; Chelation Therapy; Deferasirox; Drug Administration Schedule; Fasting; Female; Ferritins; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2017
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. European journal of haematology, 2017, Volume: 98, Issue:3 Topics: Adolescent; Adult; Benzoates; Biomarkers; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Prognosis; ROC Curve; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. American journal of hematology, 2017, Volume: 92, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chemistry, Pharmaceutical; Child; Deferasirox; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Quality of Life; Tablets, Enteric-Coated; Thalassemia; Triazoles; Young Adult	2017
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, Volume: 95, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult	2010
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International journal of hematology, 2011, Volume: 93, Issue:3 Topics: Adolescent; Adult; Asia, Southeastern; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Thalassemia; Triazoles	2011
Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Indian pediatrics, 2012, Volume: 49, Issue:4 Topics: Adolescent; Benzoates; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Triazoles; Young Adult	2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, Aug-02, Volume: 120, Issue:5 Topics: Adolescent; Adult; Aged; Algorithms; Benzoates; Blood Transfusion; Child; Deferasirox; Double-Blind Method; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Placebos; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2012
Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood cells, molecules & diseases, 2013, Volume: 50, Issue:2 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Pilot Projects; Thalassemia; Transferrin; Triazoles; Young Adult	2013

Other Studies

49 other study(ies) available for deferasirox and Thalassemias

Article	Year
Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study. Journal of pediatric hematology/oncology, 2022, 01-01, Volume: 44, Issue:1 Topics: Adolescent; Allografts; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Thalassemia	2022
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results. American journal of hematology, 2022, Volume: 97, Issue:8 Topics: Benzoates; beta-Thalassemia; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Thalassemia	2022
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. Expert review of hematology, 2023, Volume: 16, Issue:2 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia	2023
Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusion-dependent-thalassemia. British journal of haematology, 2020, Volume: 189, Issue:2 Topics: Adult; Deferasirox; Hemoglobins; Humans; Middle Aged; Tablets; Thalassemia; Young Adult	2020
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia	2021
Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatrics international : official journal of the Japan Pediatric Society, 2021, Volume: 63, Issue:4 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles	2021
Sensitive determination of deferasirox in blood of patients with thalassemia using dispersive liquid-liquid microextraction based on solidification of floating organic drop followed by HPLC-UV. Journal of pharmaceutical and biomedical analysis, 2021, Jan-30, Volume: 193 Topics: Chromatography, High Pressure Liquid; Deferasirox; Humans; Liquid Phase Microextraction; Reproducibility of Results; Thalassemia	2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica, 2022, 02-01, Volume: 107, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Risk Assessment; Risk Factors; Thalassemia; Triazoles	2022
Dual Oral Iron Chelation in Thalassemia: Need for Robust Evidence. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia	2021
Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience. Pediatric hematology and oncology, 2021, Volume: 38, Issue:6 Topics: Adolescent; Adult; Child; Deferasirox; Female; Humans; Male; Thalassemia	2021
Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective. Orphanet journal of rare diseases, 2021, 04-07, Volume: 16, Issue:1 Topics: Benzoates; Blood Transfusion; Cost of Illness; Cross-Sectional Studies; Deferasirox; Deferoxamine; Humans; Malaysia; Quality of Life; Thalassemia; Triazoles	2021
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc	2021
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. Scientific reports, 2021, 06-15, Volume: 11, Issue:1 Topics: Adult; Anemia; Chelation Therapy; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Thalassemia	2021
Adrenal insufficiency: An emerging challenge in thalassemia? American journal of hematology, 2017, Volume: 92, Issue:6 Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Adult; Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Hypoglycemia; Hypogonadism; Hypothalamo-Hypophyseal System; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelolipoma; Pituitary-Adrenal System; Shock, Septic; Thalassemia; Triazoles	2017
Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in bioscience (Landmark edition), 2018, 01-01, Volume: 23, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2018
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. La Radiologia medica, 2018, Volume: 123, Issue:8 Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey	2018
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. American journal of hematology, 2018, Volume: 93, Issue:10 Topics: Adolescent; Adult; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Thalassemia; Young Adult	2018
Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM). European journal of haematology, 2019, Volume: 102, Issue:2 Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Blood Transfusion; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Thalassemia; Treatment Outcome; Turkey	2019
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis. PloS one, 2018, Volume: 13, Issue:12 Topics: Adult; Benzoates; Blood Transfusion; Bone and Bones; Cell Differentiation; Deferasirox; Drug Evaluation; Female; Ferritins; Healthy Volunteers; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Osteoclasts; Osteoporosis; Primary Cell Culture; Pyrazoles; Receptors, Thrombopoietin; Thalassemia; Transfusion Reaction	2018
Transfusional Iron Chelation Inches Forward. Acta haematologica, 2019, Volume: 142, Issue:3 Topics: Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia	2019
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2013, Volume: 112, Issue:4 Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles	2013
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood cells, molecules & diseases, 2013, Volume: 51, Issue:2 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles	2013
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles	2013
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult	2014
The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran. Health policy (Amsterdam, Netherlands), 2015, Volume: 119, Issue:2 Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Ferritins; Health Status; Hemophilia A; Humans; Internationality; Iran; Male; Plasma; Surveys and Questionnaires; Thalassemia; Triazoles; Young Adult	2015
Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Nephrology (Carlton, Vic.), 2015, Volume: 20, Issue:12 Topics: Acidosis, Renal Tubular; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Fanconi Syndrome; Female; Hospitals, University; Humans; Hypophosphatemia; Incidence; Iron Chelating Agents; Male; Retrospective Studies; Risk Factors; Taiwan; Thalassemia; Triazoles; Young Adult	2015
Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:7 Topics: Adolescent; Benzoates; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2015
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. European journal of clinical pharmacology, 2016, Volume: 72, Issue:2 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Child, Preschool; Deferasirox; Female; Glucuronosyltransferase; Humans; Iron Chelating Agents; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymorphism, Single Nucleotide; Thalassemia; Triazoles	2016
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles	2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Indian pediatrics, 2016, Volume: 53, Issue:3 Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles	2016
Deferasirox in thalassemia patients with end-stage renal disease. American journal of hematology, 2016, Volume: 91, Issue:10 Topics: Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Kidney Failure, Chronic; Male; Middle Aged; Thalassemia; Triazoles	2016
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA. Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:6 Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Eye Diseases; Female; Humans; Iron Chelating Agents; Male; Optic Nerve; Retina; Retinal Diseases; Retrospective Studies; Siderophores; Thalassemia; Treatment Outcome; Triazoles; Visual Acuity	2017
Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Annals of hematology, 2009, Volume: 88, Issue:10 Topics: Antiviral Agents; Benzoates; Deferasirox; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Male; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2009
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles	2009
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2009
Deferasirox (Exjade) for the treatment of iron overload. Acta haematologica, 2009, Volume: 122, Issue:2-3 Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles	2009
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:5 Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Siderophores; Survival Rate; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles	2010
Iron chelation in thalassemia: time to reconsider our comfort zones. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles	2011
Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American journal of hematology, 2011, Volume: 86, Issue:5 Topics: Adolescent; Adult; Age Factors; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Medical Records; Medication Adherence; Middle Aged; North America; Retrospective Studies; Self Report; Thalassemia; Triazoles; United Kingdom; Young Adult	2011
Health-related quality of life in Thai thalassemic children treated with iron chelation. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:4 Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles	2011
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Apr-15, Volume: 893-894 Topics: Benzoates; Chromatography, High Pressure Liquid; Deferasirox; Female; Ferritins; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Statistics, Nonparametric; Thalassemia; Triazoles	2012
Thalassemia: cardiac iron and chelators. Indian pediatrics, 2012, Volume: 49, Issue:4 Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Myocardium; Thalassemia; Triazoles; Ventricular Function, Left	2012
Iron out for nontransfused thalassemia. Blood, 2012, Aug-02, Volume: 120, Issue:5 Topics: Benzoates; Deferasirox; Female; Humans; Iron Overload; Male; Thalassemia; Triazoles	2012
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult	2013
Do we need more iron-chelating drugs? Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2003
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European journal of haematology, 2008, Volume: 80, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles	2008
Transfusion-dependent thalassaemia: a new era. The Medical journal of Australia, 2008, Jan-21, Volume: 188, Issue:2 Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles	2008
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2 Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles	2001